p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane Article Swipe
Hélène Vanacker
,
Isabelle Treilleux
,
Camille Schiffler
,
Ivan Bièche
,
Mario Campone
,
Anne Patsouris
,
Mónica Arnedos
,
Paul Cottu
,
Jean-Philippe Jacquin
,
Florence Dalenc
,
Antoine Pinton
,
Nicolas Servant
,
Valéry Attignon
,
Étienne Rouleau
,
Alain Morel
,
F. Legrand
,
Marta Jimenez
,
Fabrice André
,
Thomas Bachelot
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1038/s41416-023-02549-8
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1038/s41416-023-02549-8
Related Topics
Concepts
Exemestane
Everolimus
Medicine
Metastatic breast cancer
Internal medicine
Oncology
Clinical endpoint
Breast cancer
Aromatase inhibitor
Biomarker
Hazard ratio
Letrozole
Prospective cohort study
Predictive marker
Cancer
Clinical trial
Aromatase
Confidence interval
Biology
Biochemistry
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1038/s41416-023-02549-8
- OA Status
- green
- Cited By
- 2
- References
- 33
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4390617202
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4390617202Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1038/s41416-023-02549-8Digital Object Identifier
- Title
-
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestaneWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-01-05Full publication date if available
- Authors
-
Hélène Vanacker, Isabelle Treilleux, Camille Schiffler, Ivan Bièche, Mario Campone, Anne Patsouris, Mónica Arnedos, Paul Cottu, Jean-Philippe Jacquin, Florence Dalenc, Antoine Pinton, Nicolas Servant, Valéry Attignon, Étienne Rouleau, Alain Morel, F. Legrand, Marta Jimenez, Fabrice André, Thomas BachelotList of authors in order
- Landing page
-
https://doi.org/10.1038/s41416-023-02549-8Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://pmc.ncbi.nlm.nih.gov/articles/PMC10876520/pdf/41416_2023_Article_2549.pdfDirect OA link when available
- Concepts
-
Exemestane, Everolimus, Medicine, Metastatic breast cancer, Internal medicine, Oncology, Clinical endpoint, Breast cancer, Aromatase inhibitor, Biomarker, Hazard ratio, Letrozole, Prospective cohort study, Predictive marker, Cancer, Clinical trial, Aromatase, Confidence interval, Biology, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
2Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 2Per-year citation counts (last 5 years)
- References (count)
-
33Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4390617202 |
|---|---|
| doi | https://doi.org/10.1038/s41416-023-02549-8 |
| ids.doi | https://doi.org/10.1038/s41416-023-02549-8 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/38182687 |
| ids.openalex | https://openalex.org/W4390617202 |
| fwci | 1.72524628 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D005260 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Female |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D000068338 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Everolimus |
| mesh[3].qualifier_ui | Q000188 |
| mesh[3].descriptor_ui | D001943 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | drug therapy |
| mesh[3].descriptor_name | Breast Neoplasms |
| mesh[4].qualifier_ui | Q000235 |
| mesh[4].descriptor_ui | D001943 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | genetics |
| mesh[4].descriptor_name | Breast Neoplasms |
| mesh[5].qualifier_ui | Q000473 |
| mesh[5].descriptor_ui | D001943 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | pathology |
| mesh[5].descriptor_name | Breast Neoplasms |
| mesh[6].qualifier_ui | Q000627 |
| mesh[6].descriptor_ui | D000971 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | therapeutic use |
| mesh[6].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[7].qualifier_ui | Q000627 |
| mesh[7].descriptor_ui | D000730 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | therapeutic use |
| mesh[7].descriptor_name | Androstadienes |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D015415 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Biomarkers |
| mesh[9].qualifier_ui | Q000378 |
| mesh[9].descriptor_ui | D018719 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | metabolism |
| mesh[9].descriptor_name | Receptor, ErbB-2 |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D006801 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Humans |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D005260 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Female |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000068338 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Everolimus |
| mesh[13].qualifier_ui | Q000188 |
| mesh[13].descriptor_ui | D001943 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | drug therapy |
| mesh[13].descriptor_name | Breast Neoplasms |
| mesh[14].qualifier_ui | Q000235 |
| mesh[14].descriptor_ui | D001943 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | genetics |
| mesh[14].descriptor_name | Breast Neoplasms |
| mesh[15].qualifier_ui | Q000473 |
| mesh[15].descriptor_ui | D001943 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | pathology |
| mesh[15].descriptor_name | Breast Neoplasms |
| mesh[16].qualifier_ui | Q000627 |
| mesh[16].descriptor_ui | D000971 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | therapeutic use |
| mesh[16].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[17].qualifier_ui | Q000627 |
| mesh[17].descriptor_ui | D000730 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | therapeutic use |
| mesh[17].descriptor_name | Androstadienes |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D015415 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Biomarkers |
| mesh[19].qualifier_ui | Q000378 |
| mesh[19].descriptor_ui | D018719 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | metabolism |
| mesh[19].descriptor_name | Receptor, ErbB-2 |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D006801 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Humans |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D005260 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Female |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D000068338 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Everolimus |
| mesh[23].qualifier_ui | Q000188 |
| mesh[23].descriptor_ui | D001943 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | drug therapy |
| mesh[23].descriptor_name | Breast Neoplasms |
| mesh[24].qualifier_ui | Q000235 |
| mesh[24].descriptor_ui | D001943 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | genetics |
| mesh[24].descriptor_name | Breast Neoplasms |
| mesh[25].qualifier_ui | Q000473 |
| mesh[25].descriptor_ui | D001943 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | pathology |
| mesh[25].descriptor_name | Breast Neoplasms |
| mesh[26].qualifier_ui | Q000627 |
| mesh[26].descriptor_ui | D000971 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | therapeutic use |
| mesh[26].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[27].qualifier_ui | Q000627 |
| mesh[27].descriptor_ui | D000730 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | therapeutic use |
| mesh[27].descriptor_name | Androstadienes |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D015415 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Biomarkers |
| mesh[29].qualifier_ui | Q000378 |
| mesh[29].descriptor_ui | D018719 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | metabolism |
| mesh[29].descriptor_name | Receptor, ErbB-2 |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D006801 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Humans |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D005260 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Female |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D000068338 |
| mesh[32].is_major_topic | True |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Everolimus |
| mesh[33].qualifier_ui | Q000188 |
| mesh[33].descriptor_ui | D001943 |
| mesh[33].is_major_topic | True |
| mesh[33].qualifier_name | drug therapy |
| mesh[33].descriptor_name | Breast Neoplasms |
| mesh[34].qualifier_ui | Q000235 |
| mesh[34].descriptor_ui | D001943 |
| mesh[34].is_major_topic | True |
| mesh[34].qualifier_name | genetics |
| mesh[34].descriptor_name | Breast Neoplasms |
| mesh[35].qualifier_ui | Q000473 |
| mesh[35].descriptor_ui | D001943 |
| mesh[35].is_major_topic | True |
| mesh[35].qualifier_name | pathology |
| mesh[35].descriptor_name | Breast Neoplasms |
| mesh[36].qualifier_ui | Q000627 |
| mesh[36].descriptor_ui | D000971 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | therapeutic use |
| mesh[36].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[37].qualifier_ui | Q000627 |
| mesh[37].descriptor_ui | D000730 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | therapeutic use |
| mesh[37].descriptor_name | Androstadienes |
| mesh[38].qualifier_ui | |
| mesh[38].descriptor_ui | D015415 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | |
| mesh[38].descriptor_name | Biomarkers |
| mesh[39].qualifier_ui | Q000378 |
| mesh[39].descriptor_ui | D018719 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | metabolism |
| mesh[39].descriptor_name | Receptor, ErbB-2 |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D006801 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Humans |
| mesh[41].qualifier_ui | |
| mesh[41].descriptor_ui | D005260 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | |
| mesh[41].descriptor_name | Female |
| mesh[42].qualifier_ui | |
| mesh[42].descriptor_ui | D000068338 |
| mesh[42].is_major_topic | True |
| mesh[42].qualifier_name | |
| mesh[42].descriptor_name | Everolimus |
| mesh[43].qualifier_ui | Q000188 |
| mesh[43].descriptor_ui | D001943 |
| mesh[43].is_major_topic | True |
| mesh[43].qualifier_name | drug therapy |
| mesh[43].descriptor_name | Breast Neoplasms |
| mesh[44].qualifier_ui | Q000235 |
| mesh[44].descriptor_ui | D001943 |
| mesh[44].is_major_topic | True |
| mesh[44].qualifier_name | genetics |
| mesh[44].descriptor_name | Breast Neoplasms |
| mesh[45].qualifier_ui | Q000473 |
| mesh[45].descriptor_ui | D001943 |
| mesh[45].is_major_topic | True |
| mesh[45].qualifier_name | pathology |
| mesh[45].descriptor_name | Breast Neoplasms |
| mesh[46].qualifier_ui | Q000627 |
| mesh[46].descriptor_ui | D000971 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | therapeutic use |
| mesh[46].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[47].qualifier_ui | Q000627 |
| mesh[47].descriptor_ui | D000730 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | therapeutic use |
| mesh[47].descriptor_name | Androstadienes |
| mesh[48].qualifier_ui | |
| mesh[48].descriptor_ui | D015415 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | |
| mesh[48].descriptor_name | Biomarkers |
| mesh[49].qualifier_ui | Q000378 |
| mesh[49].descriptor_ui | D018719 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | metabolism |
| mesh[49].descriptor_name | Receptor, ErbB-2 |
| type | article |
| title | p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane |
| biblio.issue | 4 |
| biblio.volume | 130 |
| biblio.last_page | 619 |
| biblio.first_page | 613 |
| topics[0].id | https://openalex.org/T12829 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9994000196456909 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Advanced Breast Cancer Therapies |
| topics[1].id | https://openalex.org/T10952 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9993000030517578 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | PI3K/AKT/mTOR signaling in cancer |
| topics[2].id | https://openalex.org/T10583 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9965000152587891 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Cancer-related Molecular Pathways |
| is_xpac | False |
| apc_list.value | 3790 |
| apc_list.currency | EUR |
| apc_list.value_usd | 4690 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2775860665 |
| concepts[0].level | 5 |
| concepts[0].score | 0.8999559879302979 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q418819 |
| concepts[0].display_name | Exemestane |
| concepts[1].id | https://openalex.org/C2779699572 |
| concepts[1].level | 2 |
| concepts[1].score | 0.8803800344467163 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q421052 |
| concepts[1].display_name | Everolimus |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.7910492420196533 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2775930923 |
| concepts[3].level | 4 |
| concepts[3].score | 0.7123228907585144 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q12859063 |
| concepts[3].display_name | Metastatic breast cancer |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.6862877011299133 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C143998085 |
| concepts[5].level | 1 |
| concepts[5].score | 0.6610654592514038 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[5].display_name | Oncology |
| concepts[6].id | https://openalex.org/C203092338 |
| concepts[6].level | 3 |
| concepts[6].score | 0.6408145427703857 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q1340863 |
| concepts[6].display_name | Clinical endpoint |
| concepts[7].id | https://openalex.org/C530470458 |
| concepts[7].level | 3 |
| concepts[7].score | 0.6188436150550842 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q128581 |
| concepts[7].display_name | Breast cancer |
| concepts[8].id | https://openalex.org/C2778504769 |
| concepts[8].level | 5 |
| concepts[8].score | 0.5635137557983398 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q3040305 |
| concepts[8].display_name | Aromatase inhibitor |
| concepts[9].id | https://openalex.org/C2781197716 |
| concepts[9].level | 2 |
| concepts[9].score | 0.5240288376808167 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q864574 |
| concepts[9].display_name | Biomarker |
| concepts[10].id | https://openalex.org/C207103383 |
| concepts[10].level | 3 |
| concepts[10].score | 0.5238268971443176 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q3930246 |
| concepts[10].display_name | Hazard ratio |
| concepts[11].id | https://openalex.org/C2778812593 |
| concepts[11].level | 5 |
| concepts[11].score | 0.45978549122810364 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q194974 |
| concepts[11].display_name | Letrozole |
| concepts[12].id | https://openalex.org/C188816634 |
| concepts[12].level | 2 |
| concepts[12].score | 0.43143728375434875 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q2113324 |
| concepts[12].display_name | Prospective cohort study |
| concepts[13].id | https://openalex.org/C2780521871 |
| concepts[13].level | 3 |
| concepts[13].score | 0.4287979006767273 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q7239671 |
| concepts[13].display_name | Predictive marker |
| concepts[14].id | https://openalex.org/C121608353 |
| concepts[14].level | 2 |
| concepts[14].score | 0.39782053232192993 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[14].display_name | Cancer |
| concepts[15].id | https://openalex.org/C535046627 |
| concepts[15].level | 2 |
| concepts[15].score | 0.2657250761985779 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q30612 |
| concepts[15].display_name | Clinical trial |
| concepts[16].id | https://openalex.org/C2776166826 |
| concepts[16].level | 4 |
| concepts[16].score | 0.23782426118850708 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q415287 |
| concepts[16].display_name | Aromatase |
| concepts[17].id | https://openalex.org/C44249647 |
| concepts[17].level | 2 |
| concepts[17].score | 0.1280040740966797 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[17].display_name | Confidence interval |
| concepts[18].id | https://openalex.org/C86803240 |
| concepts[18].level | 0 |
| concepts[18].score | 0.09114757180213928 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[18].display_name | Biology |
| concepts[19].id | https://openalex.org/C55493867 |
| concepts[19].level | 1 |
| concepts[19].score | 0.0 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[19].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/exemestane |
| keywords[0].score | 0.8999559879302979 |
| keywords[0].display_name | Exemestane |
| keywords[1].id | https://openalex.org/keywords/everolimus |
| keywords[1].score | 0.8803800344467163 |
| keywords[1].display_name | Everolimus |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.7910492420196533 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/metastatic-breast-cancer |
| keywords[3].score | 0.7123228907585144 |
| keywords[3].display_name | Metastatic breast cancer |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.6862877011299133 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/oncology |
| keywords[5].score | 0.6610654592514038 |
| keywords[5].display_name | Oncology |
| keywords[6].id | https://openalex.org/keywords/clinical-endpoint |
| keywords[6].score | 0.6408145427703857 |
| keywords[6].display_name | Clinical endpoint |
| keywords[7].id | https://openalex.org/keywords/breast-cancer |
| keywords[7].score | 0.6188436150550842 |
| keywords[7].display_name | Breast cancer |
| keywords[8].id | https://openalex.org/keywords/aromatase-inhibitor |
| keywords[8].score | 0.5635137557983398 |
| keywords[8].display_name | Aromatase inhibitor |
| keywords[9].id | https://openalex.org/keywords/biomarker |
| keywords[9].score | 0.5240288376808167 |
| keywords[9].display_name | Biomarker |
| keywords[10].id | https://openalex.org/keywords/hazard-ratio |
| keywords[10].score | 0.5238268971443176 |
| keywords[10].display_name | Hazard ratio |
| keywords[11].id | https://openalex.org/keywords/letrozole |
| keywords[11].score | 0.45978549122810364 |
| keywords[11].display_name | Letrozole |
| keywords[12].id | https://openalex.org/keywords/prospective-cohort-study |
| keywords[12].score | 0.43143728375434875 |
| keywords[12].display_name | Prospective cohort study |
| keywords[13].id | https://openalex.org/keywords/predictive-marker |
| keywords[13].score | 0.4287979006767273 |
| keywords[13].display_name | Predictive marker |
| keywords[14].id | https://openalex.org/keywords/cancer |
| keywords[14].score | 0.39782053232192993 |
| keywords[14].display_name | Cancer |
| keywords[15].id | https://openalex.org/keywords/clinical-trial |
| keywords[15].score | 0.2657250761985779 |
| keywords[15].display_name | Clinical trial |
| keywords[16].id | https://openalex.org/keywords/aromatase |
| keywords[16].score | 0.23782426118850708 |
| keywords[16].display_name | Aromatase |
| keywords[17].id | https://openalex.org/keywords/confidence-interval |
| keywords[17].score | 0.1280040740966797 |
| keywords[17].display_name | Confidence interval |
| keywords[18].id | https://openalex.org/keywords/biology |
| keywords[18].score | 0.09114757180213928 |
| keywords[18].display_name | Biology |
| language | en |
| locations[0].id | doi:10.1038/s41416-023-02549-8 |
| locations[0].is_oa | False |
| locations[0].source.id | https://openalex.org/S62966998 |
| locations[0].source.issn | 0007-0920, 1532-1827 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0007-0920 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | British Journal of Cancer |
| locations[0].source.host_organization | https://openalex.org/P4310319965 |
| locations[0].source.host_organization_name | Springer Nature |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319965 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | British Journal of Cancer |
| locations[0].landing_page_url | https://doi.org/10.1038/s41416-023-02549-8 |
| locations[1].id | pmid:38182687 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | British journal of cancer |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/38182687 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:10876520 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | |
| locations[2].pdf_url | https://pmc.ncbi.nlm.nih.gov/articles/PMC10876520/pdf/41416_2023_Article_2549.pdf |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Br J Cancer |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/10876520 |
| locations[3].id | pmh:oai:HAL:hal-04883782v1 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306402512 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | HAL (Le Centre pour la Communication Scientifique Directe) |
| locations[3].source.host_organization | https://openalex.org/I1294671590 |
| locations[3].source.host_organization_name | Centre National de la Recherche Scientifique |
| locations[3].source.host_organization_lineage | https://openalex.org/I1294671590 |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Journal articles |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | British Journal of Cancer, 2024, 130 (4), pp.613-619. ⟨10.1038/s41416-023-02549-8⟩ |
| locations[3].landing_page_url | https://hal.science/hal-04883782 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5009481448 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-9934-5719 |
| authorships[0].author.display_name | Hélène Vanacker |
| authorships[0].countries | FR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210105738 |
| authorships[0].affiliations[0].raw_affiliation_string | Centre Léon Bérard, Lyon, France |
| authorships[0].institutions[0].id | https://openalex.org/I4210105738 |
| authorships[0].institutions[0].ror | https://ror.org/01cmnjq37 |
| authorships[0].institutions[0].type | nonprofit |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210105738 |
| authorships[0].institutions[0].country_code | FR |
| authorships[0].institutions[0].display_name | Centre Léon Bérard |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Hélène Vanacker |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Centre Léon Bérard, Lyon, France |
| authorships[1].author.id | https://openalex.org/A5079971350 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-3919-5506 |
| authorships[1].author.display_name | Isabelle Treilleux |
| authorships[1].countries | FR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210105738 |
| authorships[1].affiliations[0].raw_affiliation_string | Centre Léon Bérard, Lyon, France |
| authorships[1].institutions[0].id | https://openalex.org/I4210105738 |
| authorships[1].institutions[0].ror | https://ror.org/01cmnjq37 |
| authorships[1].institutions[0].type | nonprofit |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210105738 |
| authorships[1].institutions[0].country_code | FR |
| authorships[1].institutions[0].display_name | Centre Léon Bérard |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Isabelle Treilleux |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Centre Léon Bérard, Lyon, France |
| authorships[2].author.id | https://openalex.org/A5050433884 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-0633-8988 |
| authorships[2].author.display_name | Camille Schiffler |
| authorships[2].countries | FR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210105738 |
| authorships[2].affiliations[0].raw_affiliation_string | Centre Léon Bérard, Lyon, France |
| authorships[2].institutions[0].id | https://openalex.org/I4210105738 |
| authorships[2].institutions[0].ror | https://ror.org/01cmnjq37 |
| authorships[2].institutions[0].type | nonprofit |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210105738 |
| authorships[2].institutions[0].country_code | FR |
| authorships[2].institutions[0].display_name | Centre Léon Bérard |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Camille Schiffler |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Centre Léon Bérard, Lyon, France |
| authorships[3].author.id | https://openalex.org/A5037964830 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-2430-5429 |
| authorships[3].author.display_name | Ivan Bièche |
| authorships[3].countries | FR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I80043 |
| authorships[3].affiliations[0].raw_affiliation_string | Institut Curie, Paris, France |
| authorships[3].institutions[0].id | https://openalex.org/I80043 |
| authorships[3].institutions[0].ror | https://ror.org/04t0gwh46 |
| authorships[3].institutions[0].type | nonprofit |
| authorships[3].institutions[0].lineage | https://openalex.org/I80043 |
| authorships[3].institutions[0].country_code | FR |
| authorships[3].institutions[0].display_name | Institut Curie |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Ivan Bieche |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Institut Curie, Paris, France |
| authorships[4].author.id | https://openalex.org/A5071553983 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-5196-5908 |
| authorships[4].author.display_name | Mario Campone |
| authorships[4].countries | FR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210106090 |
| authorships[4].affiliations[0].raw_affiliation_string | Institut de cancérologie de l'ouest Pays de Loire Nantes-Angers, Saint-Herblain, France |
| authorships[4].institutions[0].id | https://openalex.org/I4210106090 |
| authorships[4].institutions[0].ror | https://ror.org/01m6as704 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210106090 |
| authorships[4].institutions[0].country_code | FR |
| authorships[4].institutions[0].display_name | Institut de Cancérologie de l'Ouest |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Mario Campone |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Institut de cancérologie de l'ouest Pays de Loire Nantes-Angers, Saint-Herblain, France |
| authorships[5].author.id | https://openalex.org/A5062193270 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-9101-5424 |
| authorships[5].author.display_name | Anne Patsouris |
| authorships[5].countries | FR |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210106090 |
| authorships[5].affiliations[0].raw_affiliation_string | Institut de cancérologie de l'ouest Pays de Loire Nantes-Angers, Saint-Herblain, France |
| authorships[5].institutions[0].id | https://openalex.org/I4210106090 |
| authorships[5].institutions[0].ror | https://ror.org/01m6as704 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210106090 |
| authorships[5].institutions[0].country_code | FR |
| authorships[5].institutions[0].display_name | Institut de Cancérologie de l'Ouest |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Anne Patsouris |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Institut de cancérologie de l'ouest Pays de Loire Nantes-Angers, Saint-Herblain, France |
| authorships[6].author.id | https://openalex.org/A5086379442 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-5269-1251 |
| authorships[6].author.display_name | Mónica Arnedos |
| authorships[6].countries | FR |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I2801843802 |
| authorships[6].affiliations[0].raw_affiliation_string | Gustave Roussy, Villejuif, France |
| authorships[6].institutions[0].id | https://openalex.org/I2801843802 |
| authorships[6].institutions[0].ror | https://ror.org/0321g0743 |
| authorships[6].institutions[0].type | facility |
| authorships[6].institutions[0].lineage | https://openalex.org/I2801843802 |
| authorships[6].institutions[0].country_code | FR |
| authorships[6].institutions[0].display_name | Institut Gustave Roussy |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Monica Arnedos |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Gustave Roussy, Villejuif, France |
| authorships[7].author.id | https://openalex.org/A5034058277 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-6434-3932 |
| authorships[7].author.display_name | Paul Cottu |
| authorships[7].countries | FR |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I80043 |
| authorships[7].affiliations[0].raw_affiliation_string | Institut Curie, Paris, France |
| authorships[7].institutions[0].id | https://openalex.org/I80043 |
| authorships[7].institutions[0].ror | https://ror.org/04t0gwh46 |
| authorships[7].institutions[0].type | nonprofit |
| authorships[7].institutions[0].lineage | https://openalex.org/I80043 |
| authorships[7].institutions[0].country_code | FR |
| authorships[7].institutions[0].display_name | Institut Curie |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Paul H. Cottu |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Institut Curie, Paris, France |
| authorships[8].author.id | https://openalex.org/A5109190346 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Jean-Philippe Jacquin |
| authorships[8].countries | FR |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210111279 |
| authorships[8].affiliations[0].raw_affiliation_string | Institut de Cancérologie Lucien Neuwirth, Saint-Priest-En-Jarez, France |
| authorships[8].institutions[0].id | https://openalex.org/I4210111279 |
| authorships[8].institutions[0].ror | https://ror.org/01zss5v68 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210111279 |
| authorships[8].institutions[0].country_code | FR |
| authorships[8].institutions[0].display_name | Institute Cancer De La Loire Lucien Neuwirth |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Jean-Philippe Jacquin |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Institut de Cancérologie Lucien Neuwirth, Saint-Priest-En-Jarez, France |
| authorships[9].author.id | https://openalex.org/A5058791215 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-9854-4182 |
| authorships[9].author.display_name | Florence Dalenc |
| authorships[9].countries | FR |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210098740 |
| authorships[9].affiliations[0].raw_affiliation_string | ICR, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, France |
| authorships[9].institutions[0].id | https://openalex.org/I4210098740 |
| authorships[9].institutions[0].ror | https://ror.org/014hxhm89 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210098740 |
| authorships[9].institutions[0].country_code | FR |
| authorships[9].institutions[0].display_name | Institut universitaire du cancer de Toulouse Oncopole |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Florence Dalenc |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | ICR, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, France |
| authorships[10].author.id | https://openalex.org/A5035109792 |
| authorships[10].author.orcid | https://orcid.org/0009-0002-2801-6824 |
| authorships[10].author.display_name | Antoine Pinton |
| authorships[10].countries | FR |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I80043 |
| authorships[10].affiliations[0].raw_affiliation_string | Institut Curie, Paris, France |
| authorships[10].institutions[0].id | https://openalex.org/I80043 |
| authorships[10].institutions[0].ror | https://ror.org/04t0gwh46 |
| authorships[10].institutions[0].type | nonprofit |
| authorships[10].institutions[0].lineage | https://openalex.org/I80043 |
| authorships[10].institutions[0].country_code | FR |
| authorships[10].institutions[0].display_name | Institut Curie |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Antoine Pinton |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Institut Curie, Paris, France |
| authorships[11].author.id | https://openalex.org/A5047327833 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-1678-7410 |
| authorships[11].author.display_name | Nicolas Servant |
| authorships[11].countries | FR |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I80043 |
| authorships[11].affiliations[0].raw_affiliation_string | Institut Curie, Paris, France |
| authorships[11].institutions[0].id | https://openalex.org/I80043 |
| authorships[11].institutions[0].ror | https://ror.org/04t0gwh46 |
| authorships[11].institutions[0].type | nonprofit |
| authorships[11].institutions[0].lineage | https://openalex.org/I80043 |
| authorships[11].institutions[0].country_code | FR |
| authorships[11].institutions[0].display_name | Institut Curie |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Nicolas Servant |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Institut Curie, Paris, France |
| authorships[12].author.id | https://openalex.org/A5072873173 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Valéry Attignon |
| authorships[12].countries | FR |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210105738 |
| authorships[12].affiliations[0].raw_affiliation_string | Centre Léon Bérard, Lyon, France |
| authorships[12].institutions[0].id | https://openalex.org/I4210105738 |
| authorships[12].institutions[0].ror | https://ror.org/01cmnjq37 |
| authorships[12].institutions[0].type | nonprofit |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210105738 |
| authorships[12].institutions[0].country_code | FR |
| authorships[12].institutions[0].display_name | Centre Léon Bérard |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Valéry Attignon |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Centre Léon Bérard, Lyon, France |
| authorships[13].author.id | https://openalex.org/A5090177578 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-9046-257X |
| authorships[13].author.display_name | Étienne Rouleau |
| authorships[13].countries | FR |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I2801843802 |
| authorships[13].affiliations[0].raw_affiliation_string | Gustave Roussy, Villejuif, France |
| authorships[13].institutions[0].id | https://openalex.org/I2801843802 |
| authorships[13].institutions[0].ror | https://ror.org/0321g0743 |
| authorships[13].institutions[0].type | facility |
| authorships[13].institutions[0].lineage | https://openalex.org/I2801843802 |
| authorships[13].institutions[0].country_code | FR |
| authorships[13].institutions[0].display_name | Institut Gustave Roussy |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Etienne Rouleau |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Gustave Roussy, Villejuif, France |
| authorships[14].author.id | https://openalex.org/A5010952073 |
| authorships[14].author.orcid | https://orcid.org/0000-0003-0125-1883 |
| authorships[14].author.display_name | Alain Morel |
| authorships[14].countries | FR |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I1294671590, https://openalex.org/I154526488, https://openalex.org/I4210092509, https://openalex.org/I49451733, https://openalex.org/I97188460 |
| authorships[14].affiliations[0].raw_affiliation_string | Univ Angers, Nantes Université, Inserm, CNRS, CRCI2NA, SFR ICAT, F-49000, Angers, France |
| authorships[14].institutions[0].id | https://openalex.org/I1294671590 |
| authorships[14].institutions[0].ror | https://ror.org/02feahw73 |
| authorships[14].institutions[0].type | government |
| authorships[14].institutions[0].lineage | https://openalex.org/I1294671590 |
| authorships[14].institutions[0].country_code | FR |
| authorships[14].institutions[0].display_name | Centre National de la Recherche Scientifique |
| authorships[14].institutions[1].id | https://openalex.org/I4210092509 |
| authorships[14].institutions[1].ror | https://ror.org/003g1aw90 |
| authorships[14].institutions[1].type | facility |
| authorships[14].institutions[1].lineage | https://openalex.org/I1294671590, https://openalex.org/I1294671590, https://openalex.org/I154526488, https://openalex.org/I3019204325, https://openalex.org/I4210092509, https://openalex.org/I4210096427, https://openalex.org/I4210106090, https://openalex.org/I4210112910, https://openalex.org/I49451733, https://openalex.org/I97188460 |
| authorships[14].institutions[1].country_code | FR |
| authorships[14].institutions[1].display_name | Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers |
| authorships[14].institutions[2].id | https://openalex.org/I154526488 |
| authorships[14].institutions[2].ror | https://ror.org/02vjkv261 |
| authorships[14].institutions[2].type | government |
| authorships[14].institutions[2].lineage | https://openalex.org/I154526488 |
| authorships[14].institutions[2].country_code | FR |
| authorships[14].institutions[2].display_name | Inserm |
| authorships[14].institutions[3].id | https://openalex.org/I97188460 |
| authorships[14].institutions[3].ror | https://ror.org/03gnr7b55 |
| authorships[14].institutions[3].type | education |
| authorships[14].institutions[3].lineage | https://openalex.org/I97188460 |
| authorships[14].institutions[3].country_code | FR |
| authorships[14].institutions[3].display_name | Nantes Université |
| authorships[14].institutions[4].id | https://openalex.org/I49451733 |
| authorships[14].institutions[4].ror | https://ror.org/04yrqp957 |
| authorships[14].institutions[4].type | education |
| authorships[14].institutions[4].lineage | https://openalex.org/I49451733 |
| authorships[14].institutions[4].country_code | FR |
| authorships[14].institutions[4].display_name | Université d'Angers |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Alain Morel |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Univ Angers, Nantes Université, Inserm, CNRS, CRCI2NA, SFR ICAT, F-49000, Angers, France |
| authorships[15].author.id | https://openalex.org/A5004812301 |
| authorships[15].author.orcid | |
| authorships[15].author.display_name | F. Legrand |
| authorships[15].countries | FR |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210141925 |
| authorships[15].affiliations[0].raw_affiliation_string | UNICANCER R&D, Paris, France |
| authorships[15].institutions[0].id | https://openalex.org/I4210141925 |
| authorships[15].institutions[0].ror | https://ror.org/04vhgtv41 |
| authorships[15].institutions[0].type | healthcare |
| authorships[15].institutions[0].lineage | https://openalex.org/I4210141925 |
| authorships[15].institutions[0].country_code | FR |
| authorships[15].institutions[0].display_name | UniCancer Group |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | François Legrand |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | UNICANCER R&D, Paris, France |
| authorships[16].author.id | https://openalex.org/A5076243488 |
| authorships[16].author.orcid | https://orcid.org/0000-0002-4233-8478 |
| authorships[16].author.display_name | Marta Jimenez |
| authorships[16].countries | FR |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210141925 |
| authorships[16].affiliations[0].raw_affiliation_string | UNICANCER R&D, Paris, France |
| authorships[16].institutions[0].id | https://openalex.org/I4210141925 |
| authorships[16].institutions[0].ror | https://ror.org/04vhgtv41 |
| authorships[16].institutions[0].type | healthcare |
| authorships[16].institutions[0].lineage | https://openalex.org/I4210141925 |
| authorships[16].institutions[0].country_code | FR |
| authorships[16].institutions[0].display_name | UniCancer Group |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Marta Jimenez |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | UNICANCER R&D, Paris, France |
| authorships[17].author.id | https://openalex.org/A5001814176 |
| authorships[17].author.orcid | https://orcid.org/0000-0001-5795-8357 |
| authorships[17].author.display_name | Fabrice André |
| authorships[17].countries | FR |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I2801843802 |
| authorships[17].affiliations[0].raw_affiliation_string | Gustave Roussy, Villejuif, France |
| authorships[17].institutions[0].id | https://openalex.org/I2801843802 |
| authorships[17].institutions[0].ror | https://ror.org/0321g0743 |
| authorships[17].institutions[0].type | facility |
| authorships[17].institutions[0].lineage | https://openalex.org/I2801843802 |
| authorships[17].institutions[0].country_code | FR |
| authorships[17].institutions[0].display_name | Institut Gustave Roussy |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Fabrice Andre |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Gustave Roussy, Villejuif, France |
| authorships[18].author.id | https://openalex.org/A5041410352 |
| authorships[18].author.orcid | https://orcid.org/0000-0002-0866-9484 |
| authorships[18].author.display_name | Thomas Bachelot |
| authorships[18].countries | FR |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I4210105738 |
| authorships[18].affiliations[0].raw_affiliation_string | Centre Léon Bérard, Lyon, France |
| authorships[18].institutions[0].id | https://openalex.org/I4210105738 |
| authorships[18].institutions[0].ror | https://ror.org/01cmnjq37 |
| authorships[18].institutions[0].type | nonprofit |
| authorships[18].institutions[0].lineage | https://openalex.org/I4210105738 |
| authorships[18].institutions[0].country_code | FR |
| authorships[18].institutions[0].display_name | Centre Léon Bérard |
| authorships[18].author_position | last |
| authorships[18].raw_author_name | Thomas Bachelot |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | Centre Léon Bérard, Lyon, France |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://pmc.ncbi.nlm.nih.gov/articles/PMC10876520/pdf/41416_2023_Article_2549.pdf |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T12829 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9994000196456909 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Advanced Breast Cancer Therapies |
| related_works | https://openalex.org/W3009534276, https://openalex.org/W2952706299, https://openalex.org/W1991981105, https://openalex.org/W2046794494, https://openalex.org/W2176704754, https://openalex.org/W2090744251, https://openalex.org/W2698467764, https://openalex.org/W1978282985, https://openalex.org/W2533016636, https://openalex.org/W1941904566 |
| cited_by_count | 2 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 2 |
| locations_count | 4 |
| best_oa_location.id | pmh:oai:pubmedcentral.nih.gov:10876520 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764455111 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | PubMed Central |
| best_oa_location.source.host_organization | https://openalex.org/I1299303238 |
| best_oa_location.source.host_organization_name | National Institutes of Health |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I1299303238 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://pmc.ncbi.nlm.nih.gov/articles/PMC10876520/pdf/41416_2023_Article_2549.pdf |
| best_oa_location.version | submittedVersion |
| best_oa_location.raw_type | Text |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | Br J Cancer |
| best_oa_location.landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/10876520 |
| primary_location.id | doi:10.1038/s41416-023-02549-8 |
| primary_location.is_oa | False |
| primary_location.source.id | https://openalex.org/S62966998 |
| primary_location.source.issn | 0007-0920, 1532-1827 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0007-0920 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | British Journal of Cancer |
| primary_location.source.host_organization | https://openalex.org/P4310319965 |
| primary_location.source.host_organization_name | Springer Nature |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319965 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | British Journal of Cancer |
| primary_location.landing_page_url | https://doi.org/10.1038/s41416-023-02549-8 |
| publication_date | 2024-01-05 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W4205331907, https://openalex.org/W4239051461, https://openalex.org/W2027918295, https://openalex.org/W1861759122, https://openalex.org/W2046410395, https://openalex.org/W2152654745, https://openalex.org/W7073581486, https://openalex.org/W2113458582, https://openalex.org/W2167188058, https://openalex.org/W2884798230, https://openalex.org/W2025935112, https://openalex.org/W2395887422, https://openalex.org/W2096283457, https://openalex.org/W2111945133, https://openalex.org/W3088595788, https://openalex.org/W3100553135, https://openalex.org/W3107693991, https://openalex.org/W2078358665, https://openalex.org/W2029461564, https://openalex.org/W2140022713, https://openalex.org/W1978608178, https://openalex.org/W2965552450, https://openalex.org/W4311279381, https://openalex.org/W4281809721, https://openalex.org/W2946317931, https://openalex.org/W3012647537, https://openalex.org/W4297984276, https://openalex.org/W2891700678, https://openalex.org/W2912143634, https://openalex.org/W2967444033, https://openalex.org/W2096441602, https://openalex.org/W2056256276, https://openalex.org/W2560367415 |
| referenced_works_count | 33 |
| abstract_inverted_index | |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 95 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 19 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8100000023841858 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.75954443 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |